ProCE Banner Activity

ELEVATE-TN: 5-Yr Update of Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL

Slideset Download
Conference Coverage
After a median follow-up of approximately 5 years, acalabrutinib-based combination therapy and monotherapy maintained significantly improved PFS vs chemoimmunotherapy in patients with treatment-naive CLL with no new safety concerns.

Released: June 07, 2022

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

BMS

Daiichi Sankyo Inc

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab